Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2021 Jan 25

PMID 33488080

Citations 6

Authors

Bo Lian

Hua Wei

Ruiyan Pan

Jingui Sun

Bo Zhang

Jingliang Wu

Xiujie Li

Guixiang Tian

Affiliations

Soon will be listed here.

Abstract

Background: Tumor angiogenesis plays a crucial role in tumor development, and recent efforts have been focused on combining proapoptotic and antiangiogenic activities to enhance antitumor therapy.

Methods: In this study, galactose-modified liposomes (Gal-LPs) were prepared for co-delivery of doxorubicin (DOX) and combretastatin A4 phosphate (CA4P). The co-cultured system composed of BEL-7402 and human umbilical vein endothelial cells (HUVEC) cells was established to effectively evaluate in vitro anti-tumor activity through cell viability and cell migration assay. Furthermore, both in vivo bio-distribution and anti-hepatoma effect of DOX&CA4P/Gal-LPs were investigated on H22 tumor cell-bearing mice.

Results: The results showed that DOX&CA4P/Gal-LPs were spherical with a mean particle size of 143 nm, and could readily be taken up by BEL-7402 cells. Compared with a mixture of free DOX and CA4P, the DOX&CA4P/Gal-LPs were more effective in inhibiting cell migration and exhibited stronger cytotoxicity against BEL-7402 cells alone or a co-cultured system. The in vitro studies showed that the co-cultured system was a more effective model to evaluate the anti-tumor activity of combination therapy. Moreover, DOX&CA4P/Gal-LPs exhibited a greater anti-hepatoma effect than other drug formulations, indicating that Gal-LPs could promote drug accumulation in the tumor region and improve the anti-tumor activity.

Conclusion: Gal-LPs co-loaded with chemotherapeutic and antiangiogenic drugs are a promising strategy for anti-hepatoma therapy.

Citing Articles

Leveraging immunoliposomes as nanocarriers against SARS-CoV-2 and its emerging variants.

Mohammad Faizal N, Ramli N, Mat Rani N, Shaibie N, Aarti , Poonsawas P Asian J Pharm Sci. 2023; 18(6):100855.

PMID: 38125653 PMC: 10730353. DOI: 10.1016/j.ajps.2023.100855.

Chitosan-based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy.

Ashrafizadeh M, Hushmandi K, Mirzaei S, Bokaie S, Bigham A, Makvandi P Bioeng Transl Med. 2023; 8(1):e10325.

PMID: 36684100 PMC: 9842052. DOI: 10.1002/btm2.10325.

Improving the Effect of Cancer Cells Irradiation with X-rays and High-Energy Protons Using Bimetallic Palladium-Platinum Nanoparticles with Various Nanostructures.

Klebowski B, Stec M, Depciuch J, Panek A, Krzempek D, Komenda W Cancers (Basel). 2022; 14(23).

PMID: 36497386 PMC: 9736524. DOI: 10.3390/cancers14235899.

Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomes-A Preliminary Study.

Bartos A, Iancu I, Ciobanu L, Onaciu A, Moldovan C, Moldovan A Nanomaterials (Basel). 2022; 12(16).

PMID: 36014698 PMC: 9414144. DOI: 10.3390/nano12162833.

Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer.

Li Y, Zhang R, Xu Z, Wang Z Int J Nanomedicine. 2022; 17:909-925.

PMID: 35250267 PMC: 8893038. DOI: 10.2147/IJN.S349426.

References

Jiang S, Li M, Hu Y, Zhang Z, Lv H . Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma. Carbohydr Polym. 2018; 197:194-203. DOI: 10.1016/j.carbpol.2018.05.090. View

Zhou Q, Zhou Y, Liu X, Shen Y . GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment. Sci Rep. 2017; 7(1):13379. PMC: 5645386. DOI: 10.1038/s41598-017-13869-0. View

Huang Y, Hu L, Huang S, Xu W, Wan J, Wang D . Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration. Int J Nanomedicine. 2018; 13:8309-8323. PMC: 6289229. DOI: 10.2147/IJN.S184379. View

Yang S, Tang Z, Hu C, Zhang D, Shen N, Yu H . Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors. Adv Mater. 2019; 31(11):e1805955. DOI: 10.1002/adma.201805955. View

Carmeliet P, Jain R . Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473(7347):298-307. PMC: 4049445. DOI: 10.1038/nature10144. View

Zhang B, Wang T, Yang S, Xiao Y, Song Y, Zhang N . Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy. J Control Release. 2016; 238:10-21. DOI: 10.1016/j.jconrel.2016.07.022. View

Zou Y, Song Y, Yang W, Meng F, Liu H, Zhong Z . Galactose-installed photo-crosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice. J Control Release. 2014; 193:154-61. DOI: 10.1016/j.jconrel.2014.05.016. View

Dutta R, Mahato R . Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017; 173:106-117. PMC: 5777523. DOI: 10.1016/j.pharmthera.2017.02.010. View

Li F, Wang Y, Chen W, Wang D, Zhou Y, You B . Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect Multi-functional Nanoparticles for Orthotopic Non-Small Cell Lung Cancer Treatment. Theranostics. 2019; 9(20):5886-5898. PMC: 6735374. DOI: 10.7150/thno.32416. View

10.

Wang J, Wu Z, Pan G, Ni J, Xie F, Jiang B . Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes. Nanomedicine. 2017; 14(6):1949-1961. DOI: 10.1016/j.nano.2017.09.012. View

11.

Chountoulesi M, Demetzos C . Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System. Brain Sci. 2020; 10(6). PMC: 7349417. DOI: 10.3390/brainsci10060338. View

12.

Byrne J, Jajja M, ONeill A, Bickford L, Keeler A, Hyder N . Local iontophoretic administration of cytotoxic therapies to solid tumors. Sci Transl Med. 2015; 7(273):273ra14. PMC: 4545246. DOI: 10.1126/scitranslmed.3009951. View

13.

Ojha T, Pathak V, Shi Y, Hennink W, Moonen C, Storm G . Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Adv Drug Deliv Rev. 2017; 119:44-60. PMC: 5919100. DOI: 10.1016/j.addr.2017.07.007. View

14.

Hu H, Xiao C, Wu H, Li Y, Zhou Q, Tang Y . Nanocolloidosomes with Selective Drug Release for Active Tumor-Targeted Imaging-Guided Photothermal/Chemo Combination Therapy. ACS Appl Mater Interfaces. 2017; 9(48):42225-42238. DOI: 10.1021/acsami.7b14796. View

15.

Madamsetty V, Sharma A, Toma M, Samaniego S, Gallud A, Wang E . Tumor selective uptake of drug-nanodiamond complexes improves therapeutic outcome in pancreatic cancer. Nanomedicine. 2019; 18:112-121. PMC: 6588439. DOI: 10.1016/j.nano.2019.02.020. View

16.

Shen N, Wu J, Yang C, Yu H, Yang S, Li T . Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment. Nano Lett. 2019; 19(11):8021-8031. DOI: 10.1021/acs.nanolett.9b03214. View

17.

Malam Y, Loizidou M, Seifalian A . Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009; 30(11):592-9. DOI: 10.1016/j.tips.2009.08.004. View

18.

Liu T, Zhang D, Song W, Tang Z, Zhu J, Ma Z . A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor. Acta Biomater. 2017; 53:179-189. DOI: 10.1016/j.actbio.2017.02.001. View

19.

Tewari K, Sill M, Long 3rd H, Penson R, Huang H, Ramondetta L . Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370(8):734-43. PMC: 4010094. DOI: 10.1056/NEJMoa1309748. View

20.

Cao J, Gao X, Cheng M, Niu X, Li X, Zhang Y . Reversible Shielding between Dual Ligands for Enhanced Tumor Accumulation of ZnPc-Loaded Micelles. Nano Lett. 2019; 19(3):1665-1674. DOI: 10.1021/acs.nanolett.8b04645. View